Meeting
2021 ASCO Annual Meeting
A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors.
Authors
Patricia LoRusso
Yale University School of Medicine, Yale Cancer Center, New Haven, CT
Patricia LoRusso , Mrinal M. Gounder , Manish R. Patel , Noboru Yamamoto , Todd Michael Bauer , Scott Laurie , Rolf Grempler , Teffany Davenport , Junxian Geng , Maren Rohrbacher , Mehdi Lahmar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT03449381
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3016)
DOI
10.1200/JCO.2021.39.15_suppl.3016
Abstract #
3016
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors.
First Author: David Sommerhalder
Poster
2022 ASCO Annual Meeting
A first-in-human phase 1 dose escalation study of FF-10850 (liposomal topotecan) in patients with advanced solid tumors.
First Author: Ursula A. Matulonis
Poster
2012 ASCO Annual Meeting
Phase I dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.
First Author: Takashi Seto
Poster
2012 ASCO Annual Meeting
Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors.
First Author: Herlinde Dumez